The Blueprint Medicines Corp (BPMC) share price is expected to increase by 6.53% over the next year. This is based on calculating the average 12-month share price estimate provided by 13 stock analysts who have covered BPMC. Price targets range from $50.00 at the low end to $114.00 at the high end. The current analyst consensus for BPMC is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 13 Wall Street analysts have assigned BPMC 10 buy ratings, 1 hold ratings, and 2 sell ratings. This means that analysts expect Blueprint Medicines Corp to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BPMC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
andrew berens Leerink Partners | Sell | $50.0 | maintained | Feb 16, 2024 |
david lebovitz Citi | Sell | $54.0 | maintained | Dec 11, 2023 |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
When did it IPO
2015
Staff Count
655
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Ms. Kathryn Haviland
Market Cap
$5.34B
In 2023, BPMC generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BPMC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
LANC-USD
$193.94
$21.58
CNXC-USD
$81.94
$53.37
FCFS-USD
$117.29
NUVL-USD
$86.21